Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced an upcoming conference call to discuss its fiscal second quarter 2023 results on May 12, 2023, at 8:00 a.m. ET. The call will cover financial results, operational updates, and include a Q&A session. Interested parties can access the live webcast through the company's investor relations website or via teleconference. A replay of the call will be available later that day and archived for one year.
With a legacy of nearly 100 years in insulin delivery and a dedicated workforce of approximately 2,000 employees, Embecta aims to empower individuals with diabetes through innovative solutions.
Embecta Corp. (Nasdaq: EMBC) is hosting a symposium at the ATTD 2023 conference on February 24, 2023, emphasizing the crucial role of people with diabetes in their care. Titled “Diabetes Era of Possibilities: Infusing PwD Choice into Practice!”, the session aims to enhance treatment personalization and discuss insulin injection techniques and diabetes technologies for improved outcomes. The symposium will be chaired by Prof. Dr. Lutz Heinemann and feature key speakers from the diabetes healthcare community. The event underscores the importance of collaboration in care plans to improve the quality of life for diabetes patients.
Embecta Corp. (Nasdaq: EMBC) reported its Q1 fiscal year 2023 results, with revenues of $275.7 million, down 4.7% year-over-year. Adjusted net income was $55.4 million, or $0.96 per diluted share. While U.S. revenues fell 1.1%, international revenues decreased 8.7%, though they rose 2.6% in constant currency. The company raised its fiscal year 2023 revenue guidance to $1,084 - $1,107 million, expecting a 4.0% - 2.0% decline reported and -1.5% - 0.5% in constant currency. A quarterly dividend of $0.15 per share was announced. The CEO expressed confidence in achieving strategic priorities and sustainable success.